News and Announcements

GSK to buy Boston-based biopharma firm Nuvalent for $10.6bn

By Michele Maatouk

Date: Tuesday 09 Jun 2026

(Sharecast News) - GSK said on Tuesday that it has agreed to buy Boston-based oncology-focused biopharmaceutical firm Nuvalent for $10.6bn (£7.9bn).
The FTSE 100 company will pay $124 per share, which is a 40% premium to the last closing price.

GSK said the deal is consistent with its strategy of...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page